Michael Gregor - Department of Haematology, Luzerner Kantonsspital

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 59 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

First-line Venetoclax Combinations Versus Chemoimmunotherapy in Fit Patients with Chronic Lymphocytic Leukaemia (GAIA/CLL13): 4-Year Follow-Up from a Multicentre, Open-Label, Randomised, Phase 3 Trial

The Lancet Oncologyno. 6 (2024): 744-759

Cited0Views0WOSBibtex

Therapy Management and Outcomes in Newly Diagnosed Unfit AML Patients Receiving Venetoclax Plus HMA - Insights from a Prospective Real-World Study in Switzerland and Austria

Thomas Pabst, Thomas Lehmann,Petra Pichler,Sigrid Machherndl-Spandl,Michael Gregor,Jeroen S. Goede,Sabine Gerull, Daniel Maria Mayer, Jean-Francois Lambert, Catherine Germanier,Georg Stuessi

BLOOD (2024): 2413-2414

Cited0Views0Bibtex

Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: an Analysis from the Phase 3 GAIA/CLL13 Trial

Bloodno. Supplement 1 (2024): 3238-3238

Cited0Views0Bibtex

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

BLOOD (2023)

Cited0Views0Bibtex

Développements Récents En Hématologie, Teil 1

Forum médical suisse (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn